Initial therapy of HIV infection

被引:61
作者
Gallant, JE [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21287 USA
关键词
investigational drugs; initial therapy; HAART; resistance; salvageability; naive patients;
D O I
10.1016/S1386-6532(02)00024-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: The use of antiretroviral therapy has improved the quality of life and has increased the survival of HIV-infected individuals. However, the rapid rate of virus mutation and subsequent emergence of drug-resistant HIV variants threaten the longer-term efficacy of HIV treatment. The initial regimen provides the greatest chance for lasting suppression of viral load. Aims: Appropriate selection of the initial antiretroviral regimen is critical. The growing number of drug classes allows healthcare providers to individualize treatment regimens. Factors influencing the selection of first-line therapy include baseline viral load and CD4 count, drug pharmacokinetics, potency, tolerability, safety, resistance and salvageability. Characteristics likely to affect adherence, such as regimen complexity and pill burden, must also be considered, as poor adherence is the most common cause of treatment failure. Conclusion: The selection of the initial regimen requires consideration of several factors. Drugs from new classes as well as new drugs from existing classes with favorable resistance and side effect profiles are in various stages of development. Many of these drugs will enhance available options for initial therapy. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:317 / 333
页数:17
相关论文
共 84 条
  • [21] ERON J, 2001, 8 C RETR OPP INF CHI
  • [23] Fischl MA, 1999, AIDS, V13, pS49
  • [24] FISKE WD, 2000, 7 C RETR OPP INF 30
  • [25] HIV-protease inhibitors
    Flexner, C
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) : 1281 - 1292
  • [26] Strategies for long-term success in the treatment of HIV infection
    Gallant, JE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (10): : 1329 - 1334
  • [27] Anti-HIV effect of saquinavir combined with ritonavir is limited by previous long-term therapy with protease inhibitors
    Gatanaga, H
    Aizawa, S
    Kikuchi, Y
    Tachikawa, N
    Genka, I
    Yoshizawa, S
    Yamamoto, Y
    Yasuoka, A
    Oka, S
    [J]. AIDS RESEARCH AND HUMAN RETROVIRUSES, 1999, 15 (17) : 1493 - 1498
  • [28] In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632
    Gong, YF
    Robinson, BS
    Rose, RE
    Deminie, C
    Spicer, TP
    Stock, D
    Colonno, RJ
    Lin, PF
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (09) : 2319 - 2326
  • [29] Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy
    Grabar, S
    Le Moing, V
    Goujard, C
    Leport, C
    Kazatchkine, MD
    Costagliola, D
    Weiss, L
    [J]. ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) : 401 - 410
  • [30] GRUZDEV B, 2001, 41 INT C ANT AG CHEM